Physician profile
Freya Marshall
NPI 1760711220
$10,043.19
in general payments reported to CMS, 2019-2025
35 companies · $413 in 2025
The $413 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $442 · 2021: $559 · 2022: $1,138 · 2023: $321 · 2024: $6,846 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Food and Beverage: $1,553 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Food and Beverage | $1,552.99 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Human Regenerative Technologies | $6,000.00 | 2024 | |
| Medtronic, INC. | $589.66 | 2021-2025 | Truclear, Ligasure |
| Therapeuticsmd, INC. | $398.52 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $344.05 | 2021-2024 | |
| Abbvie INC. | $336.54 | 2020-2023 | |
| Biom'Up France Sas | $321.20 | 2020-2021 | |
| Organon LLC | $222.63 | 2022-2024 | Nexplanon |
| Astellas Pharma US INC | $191.44 | 2022-2024 | Veozah |
| Pfizer INC. | $187.59 | 2021-2024 | |
| Myovant Sciences INC. | $155.44 | 2022 | |
| Sage Therapeutics, LLC | $150.62 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $129.22 | 2019-2022 | |
| Millicent US INC | $114.29 | 2024-2025 | Femring, Intrarosa |
| Shield Therapeutics INC | $96.48 | 2022-2024 | Accrufer |
| Meditrina | $95.87 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $85.00 | 2024-2025 | Myfembree, Gemtesa |
| Roche Diagnostics Corporation | $78.16 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $75.81 | 2019 | |
| Novo Nordisk INC | $56.07 | 2019-2023 | Wegovy |
| Exeltis, USA INC. | $45.38 | 2023-2024 | Slynd |
| Ethicon US, LLC | $45.27 | 2024 | Vistaseal, Surgicel Nu-Knit |
| Bayer Healthcare Pharmaceuticals INC. | $43.16 | 2024-2025 | |
| Minerva Surgical, INC | $29.74 | 2023 | |
| Cepheid | $26.46 | 2025 | Genexpert |
| Evofem Biosciences, INC. | $26.08 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $25.85 | 2025 | Qelbree |
| Tempus Ai, INC | $24.00 | 2024 | |
| Ascend Therapeutics US, LLC | $23.36 | 2024 | |
| Scynexis, INC. | $20.12 | 2022 | |
| Agile Therapeutics, INC. | $20.02 | 2024 | Twirla |
| Exact Sciences Corporation | $19.59 | 2024 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $18.30 | 2019 | |
| Acella Pharmaceuticals, LLC | $17.40 | 2025 | NP Thyroid 60 |
| Smith+Nephew, INC. | $16.17 | 2025 | Stravix Pl |
| Medicem INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freya Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.